Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 19/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 19/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 19/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 19/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.43 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.43 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Morpholine SCHEMBL4593148 | 0.87 | MAPK14 (0.49) | MAPK13MAPK12MAPK11MAPK14MAP4K4 | |
| Morpholine SCHEMBL7458976 | 0.85 | MAPK14 (0.68) | MAPK13MAPK12MAPK11MAPK14MAP4K4 | |
| Morpholine SCHEMBL8860558 | 0.81 | TLR8 (0.42) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| Morpholine SCHEMBL8611502 | 0.80 | MAPK14 (0.70) | MAPK13MAPK12MAPK11MAPK14 | |
| Morpholine SCHEMBL4585315 | 0.78 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL6420895 | 0.73 | MAPK14 (0.70) | MAPK13MAPK12MAPK11MAPK14MAP4K4 | |
| SCHEMBL4916578 | 0.72 | MAPK14 (0.69) | MAPK13MAPK12MAPK11MAPK14MAP4K4 | |
| Morpholine SCHEMBL8860407 | 0.69 | TLR8 (0.36) | MAPK13MAPK12MAPK11MAPK14CSNK1D | |
| SCHEMBL29975048 | 0.68 | MAPK13 (0.90) | MAPK13MAPK12MAPK11MAPK14MAP4K4 | |
| SCHEMBL8177432 | 0.67 | MAPK14 (0.72) | MAPK13MAPK12MAPK11MAPK14MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1291346-B1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORP (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-0708768-B1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 2003-04-09 | — | — | EP | disclosed |
| EP-1291346-A1 | Process for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020188122-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2002-12-12 | — | — | US | disclosed |
| EP-1229035-A1 | Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| EP-1227091-A2 | Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SMITHKLINE BEECHAM CORPORATION (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-1227092-A2 | Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties | SmithKline Beecham Corporation (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6222036-B1 | REACTING 2-THIO-4-DIMETHYOXYMETHYL-PYRIMIDINE WITH ACETIC ACID AND CATALYTIC AMOUNT OF CONCETRATED SULFURIC ACID TO PRODUCE 2-THIOPYRIMIDINE ALDEHYDE | SMITHKLINE BEECHAM CORPORATION | 2001-04-24 | — | — | US | disclosed |
| US-6150557-A | REACTING COMPOUND CONTAINING SECONDARY AMIDE GROUPS WITH BENZENESULFINIC ACID OR ITS DERIVATIVE IN PRESENCE OF ACID CATALYST | SMITHKLINE BEECHAM CORPORATION (US) | 2000-11-21 | — | — | US | disclosed |
| US-6103936-A | REACTING ALDEHYDE, SULFIDE, SULFONE, OR SULFOXIDE WITH FORMAMIDE IN PRESENCE OF ACID CATALYST, AND OPTIONALLY A DEHYDRATING AGENT | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-15 | — | — | US | disclosed |
| US-5969184-A | INTERMEDIATES FOR COMPOUNDS WHICH CONTROL PRODUCTION OF EXCESSIVE INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5663334-A | CYTOKINE INHIBITORS FORMED BY REACTION OF IMINE WITH SULFUR SUBSTITUTED NITRILE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-09-02 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188122-A1 | Novel compounds | IL2, IFNG, IL1RN | MAPK13 680/4885MAPK12 1002/4885MAPK11 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.